Explority AI launches open rare disease drug discovery hub

Explority AI has launched an open-access intelligence hub covering 5,846 rare diseases to help pharma and biotech teams assess early drug discovery opportunities faster. The platform combines population, treatment, research, and orphan-drug data in one place, aiming to cut weeks of manual research and support better R&D and business development decisions.

Why it matters: - Rare diseases affect more than 300 million people worldwide, but the information needed to evaluate drug opportunities is spread across registries, clinical guidelines, drug databases, and published papers. - Explority AI says the new hub can save weeks of manual research and reduce decisions based on outdated or incomplete information. - The platform is designed to help pharma, biotech, patient advocates, and investors assess unmet need and opportunity in an area where new therapies can have outsized impact.

What happened: - Explority AI launched an open-access intelligence hub for rare disease drug discovery covering 5,846 rare diseases. - The hub brings disease-level information into a single searchable directory for early-stage R&D and business development. - The company said the launch closes the gap between academic research and the pharmaceutical industry in early-stage drug discovery. - Andrew Obolenskiy, co-founder and CEO of Explority AI, said opening the directory means researchers, R&D teams, and business development teams no longer need to rebuild the landscape from scratch for each rare disease.

The details: - Each disease page includes population and burden figures, standard-of-care gaps, literature overviews, live research activity, and drug-discovery landscape data for emerging orphan therapies. - The hub also includes a comprehensive table of orphan drug designations associated with each disease. - The underlying data is built and continuously updated from a corpus of more than 1 million scientific papers on drug discovery. - That same corpus powers Explority AI’s models for forecasting the probability of success in clinical trials. - The directory updates as new papers are published and new designations are granted. - Users can screen diseases across therapy types including small molecules, antibodies, therapeutic proteins, RNA therapies, and gene and cell therapies.

Between the lines: - Many pharma research tools charge for basic disease landscaping, which can slow the earliest and most information-heavy stage of drug discovery. - Making the directory free appears aimed at widening access to early-stage intelligence and accelerating drug repurposing and orphan-drug development. - Explority AI is pairing the hub with its core forecasting product, which adds a forward-looking layer to the market and scientific context around each disease. - Orphan therapies represented a majority of recent FDA approvals, at 54% in 2025, which helps explain why rare-disease pipelines remain a priority for pharma, biotech, and life-science investors.

What’s next: - Explority AI says the hub will continue to update continuously as the research and orphan-drug landscape changes. - Pharma and biotech teams can use the directory for deal sourcing, in-licensing evaluation, and early-stage R&D planning. - The company is positioning the platform as a free entry point to rare-disease intelligence alongside its probability-of-success forecasting tools.

The bottom line: - Explority AI is betting that open, continuously updated rare-disease intelligence will make early drug discovery faster, cheaper, and less error-prone.